FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/12/2023
Back to search
Official data from USPTO
RIKEN-NKT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
11/12/2023
Trademark type
Combined
Nice classes
5, 44
Filing date
07/30/2021
Registration date
06/27/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/27/2023
Last transaction
06/27/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
JP
Examiner
HUDSON, TAMARA
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "RIKEN-NKT" in stylized orange font, with the letter "R" forming an orange infinity symbol to the upper left of the letter; the color white in the mark indicates background and is not claimed as a feature of the mark.
Holders and representatives
Holders
RIKEN IMMUNE REGENERATIVE MEDICINE INC.
Representatives
M. Scott Alprin Alprin Law Offices, P.C.
Technical classification
Nice Classes
Class 5Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Cells for medical use or clinical use; cells for medical use or clinical use for treatment or prevention of cancer; cells as pharmaceutical for treatment or prevention of cancer; biological preparations for use in cell cultures for medical purposes for the treatment of cancerimmune diseaseallergic diseasediabetesmyasthenia including lambert-Eaton syndromeParkinson's diseaserenal failuredementia; cellular function activating agents for medical purposes; pharmaceutical preparations for activating cellular function; pharmaceutical preparationsother than agrochemicalsfor the treatment of cancerimmune diseaseallergic diseasediabetesmyasthenia including lambert-Eaton syndromeParkinson's diseaserenal failuredementia; reagent paper for medical purposes; nutritional supplements; dietetic preparations adapted for medical purposes
Class 44
Medical treatment services utilizing cell growth or cell activation and consultancy and information services relating thereof; medical treatment or prevention of cancer utilizing cell growth or cell activation and consultancy and information services relating thereof; providing medical cancer treatment and consultancy and information services relating thereof; medical servicesproviding clinical examinations related to medical treatment and consultancy and information services relating thereof; medical servicesproviding clinical examinations and medication thereof as well as consultancy and information services relating thereof; medical treatment services and consultancy and information services relating thereof; medical check-up services and consultancy and information services relating thereof; dental care services; provision of pharmaceutical information relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals
Publications
History of USPTO decisions and trademark events.
37 publications found
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
09/29/2023
XXCR
GENERIC MADRID TRANSACTION CREATED
09/29/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/27/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/27/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
06/27/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
06/06/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/17/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
05/17/2023
GPNX
NOTIFICATION PROCESSED BY IB
04/13/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/11/2023
PUBO
PUBLISHED FOR OPPOSITION
04/11/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/22/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/22/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/22/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/06/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/24/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/24/2023
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
02/24/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
09/01/2022
GNFR
FINAL REFUSAL E-MAILED
09/01/2022
CNFR
FINAL REFUSAL WRITTEN
09/01/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/21/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/21/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/21/2022
RFNT
REFUSAL PROCESSED BY IB
06/28/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/08/2022
RFRR
REFUSAL PROCESSED BY MPU
06/08/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/05/2022
CNRT
NON-FINAL ACTION WRITTEN
05/04/2022
DOCK
ASSIGNED TO EXAMINER
04/28/2022
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
02/02/2022
ALIE
ASSIGNED TO LIE
02/01/2022
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
01/28/2022
MAFR
APPLICATION FILING RECEIPT MAILED
12/22/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/18/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/16/2021
Continuous trademark protection
Get notified about every new filing that threatens RIKEN-NKT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.